RxDoctor Payments Data

Bonnie Her, MD

Family Medicine · Fresno, CANPI 1932457736

Payments from drug & device makers

$4,562in general payments, 2019–2025

Across 235 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$897
  • Novo Nordisk$669
  • Takeda Pharmaceuticals U.S.A., Inc.$356
  • Boehringer Ingelheim$293
  • AbbVie$253
  • Lilly USA, LLC$245
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,46998%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,562 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$128,223
Medicare patients
215
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$112,145
OzempicSemaglutide34$38,576
TrulicityDulaglutide25$38,064
EliquisApixaban13$17,985
Repatha SureclickEvolocumab11$17,790
Breo ElliptaFluticasone/Vilanterol17$7,222
Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br12$6,735
SynthroidLevothyroxine Sodium85$6,666
Rosuvastatin Calcium332$3,215
Clonidine13$2,064
Escitalopram Oxalate75$1,677
Gabapentin57$1,531
Bupropion XlBupropion Hcl48$1,530
Levothyroxine Sodium124$1,497
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide20$1,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$293$112,14585 claims
Novo NordiskOzempic$669$38,57634 claims
Lilly USA, LLCTrulicity$245$38,06425 claims
PfizerEliquis$207$17,98513 claims
GSKBreo Ellipta$234$7,22217 claims
AbbVieSynthroid$253$6,66685 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →